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Summary
Molecular imaging of fibrin offers a sensitive way to
detect ruptured atherosclerotic plaque with MRI. To
date we and others have heavily explored the use of
gadolinium and manganese as paramagnetic metals to
provide T1 contrast. In this project, we developed the
first bivalent copper nanocolloids for MR molecular
imaging of thrombus.
Background
Robust detection of fibrin expressed in the microfissues
of ruptured plaque of the carotid artery offers an oppor-
tunity to intercede prophylatically in patients at high
risk for stroke. Given the abundance of fibrin in micro-
thrombus, we have focused on developing gadolinium-
free nanomedicine strategies for paramagnetic imaging
of clot, respecting recent concerns regarding the patho-
logical link between the lanthanide and Nephrogenic
Systemic Fibrosis in patients with severe renal disease.
The objective of this research was to develop and char-
acterize the first molecular imaging (MI) agent for fibrin
using copper-based nanocolloids (NanoQ).
Methods
Nanocolloids incorporating copper (II) complexes were
synthesized (Dav=217 nm, ζ=-13mV) and characterized
for MI of thrombus. MR properties of NanoQ in sus-
pension were defined at 3.0 T at 25°C. Single slice inver-
sion recovery and multi-echo spin echo sequences were
used to calculate the ionic (per metal) and particulate
(per particle) relaxivities from serial dilutions. T1-
weighted gradient echo imaging of fibrin clots with
NanoQ or a control (n=3/group) using fibrin-specific
antibodies (NIB5F3) were acquired. In vivo pharmacoki-
netics and 24 hour biodistribution, and bioelimination
of NanoQ were evaluated in rodents.
Results
The particulate relaxivity of the NanoQ was high,
r1=66,000±2200 (s●mmol [NanoQ])-1, while the ionic
r1 relaxivitiy (4.3±0.1 (s●mmol [Cu])-1) was similar to
Gd-DTPA. The particulate r2 relaxivities were
r2=135,000±2900 and ionic r2 relaxivities of 10.4±0.34
(s●mmol [Cu])-1, respectively. NanoQ targeted to fibrin
clot phantoms provided strong improvement in con-
trast-to-noise ratio (CNR) (40x p<0.05), while control
clots (non-targeted and targeted no metal) had negligi-
ble contrast enhancement. NanoQ given intravenously
as a bolus had a long half-life (100 min, n=3) deter-
mined by fitting two-compartment bi-exponential model
fit (R2>0.99). ICP analysis of tissue copper 24 hours
post injection revealed that approximately 90% of the
metal was already eliminated from the animal.
Conclusions
Fibrin-specific NanoQ is a first high T1 relaxivity biva-
lent copper nanoparticluate MI agent that could afford
sensitive noninvasive MR imaging of thrombus asso-
ciated with ruptured plaques in high risk patients.
Funding
NIH.
Author details
1Medicine, Washington University Medical School, Saint Louis, MO, USA.
2Surgery, Saint Thomas’, London, UK.
Published: 1 February 2012
1Medicine, Washington University Medical School, Saint Louis, MO, USA
Full list of author information is available at the end of the article
Pan et al. Journal of Cardiovascular Magnetic Resonance 2012, 14(Suppl 1):O42
http://www.jcmr-online.com/content/14/S1/O42
© 2012 Pan et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.doi:10.1186/1532-429X-14-S1-O42
Cite this article as: Pan et al.: Copper nanocolloids: a new thrombus
molecular imaging approach to ruptured plaque. Journal of
Cardiovascular Magnetic Resonance 2012 14(Suppl 1):O42.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Figure 1 Top: Contrast to Noise ratio (CNR) of fibrin targeted
copper nanocolloids (NanoQ) versus nontargeted and control
groups at 1.5 and 3T using T1w GRE MR. Bottom: Single slice
images of fibrin-rich clots treated with fibrin-targeted NanoQ,
nontargeted NanoQ, and control (no treatment) obtained at 3T
using a T1w GRE pulse sequence.
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